Page 370 - Read Online

Sommariva. J Cancer Metastasis Treat 2017;3:362-7 Journal of
DOI: 10.20517/2394-4722.2017.37
Cancer Metastasis and Treatment

www.jcmtjournal.com
Minireview Open Access

Treatment of liver metastases in patients

selected for cytoreductive surgery and

hyperthermic intraperitoneal chemotherapy

for colorectal peritoneal carcinomatosis

Antonio Sommariva

Surgical Oncology Unit, Veneto Institute of Oncology IOV - IRCCS, 35128 Padova, Italy.
Correspondence to: Dr. Antonio Sommariva, Surgical Oncology Unit, Veneto Institute of Oncology IOV - IRCCS, via Gattamelata 64, 35128 Padova,
Italy. E-mail: antonio.sommariva@iov.veneto.it

How to cite this article: Sommariva A. Treatment of liver metastases in patients selected for cytoreductive surgery and hyperthermic
intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis. J Cancer Metastasis Treat 2017;3:362-7.

ABSTRACT
Article history: Cytoreductive surgery (CS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have
Received: 25 May 2017 gained increasing consensus in treatment of peritoneal carcinomatosis from colorectal
First Decision: 19 Sep 2017 cancer. The presence of liver metastases is generally considered a contraindication for CS
Revised: 9 Oct 2017 + HIPEC, as hepatic involvement no longer represents a loco-regional aspect of disease.
Accepted: 20 Oct 2017 Despite this, liver resection (LR) has been tested in selected cases in combination with CS
Published: 21 Dec 2017 + HIPEC for treatment of peritoneal carcinomatosis with liver metastasis. Relevant studies
on this topic were identified through a search in the electronic PubMed database, using the
Key words: appropriate keywords. CS + HIPEC + LR allows similar outcomes in terms of survival and
Colorectal cancer, morbidity with respect to CS + HIPEC, especially in patients with low tumor load. CS +
peritoneal carcinomatosis, HIPEC + LR represents a reasonable approach for patients with peritoneal carcinomatosis
liver metastases, and liver metastases from colorectal cancer. Patients should be selected in high volume
hyperthermic intraperitoneal tertiary centres, preferably in the context of a prospective trial.
chemotherapy,
liver resection

INTRODUCTION varies between 5 and 7 months . The introduction
[3]
of systemic chemotherapy treatment regimes, based
on oxaliplatin and irinotecan alone or associated with
Peritoneal carcinomatosis (PC) from colorectal vascular endothelial growth factor (VEGF)-inhibitors
carcinoma is present in about 10% of patients at the (in various combinations and treatment sequences),
time of diagnosis, and appears in 25% of patients has enabled a significant improvement in outcome
during follow-up [1,2] . Median survival of patients for patients with metastatic colorectal cancer (MCC),
affected by colorectal peritoneal carcinomatosis where in some trials a median survival greater than

Quick Response Code:
This is an open access article licensed under the terms of Creative Commons Attribution 4.0 International
License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution,
and reproduction in any medium, as long as the original author is credited and the new creations are licensed under the
identical terms.
For reprints contact: service@oaepublish.com

362 © The Author(s) 2017 www.oaepublish.com